The Top 5 Biosimilar Articles for the Week of March 15

March 19, 2021

Here are the top 5 biosimilar articles for the week of March 15, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 15, 2021.

Number 5: "Shocked" by the threat of competition, originator manufacturers start raising prices long before rival products appear on the scene, investigators found.

Number 4: Alvotech closes on $35 million in funding, and Samsung Bioepis gets closer to marketing an adalimumab biosimilar.

Number 3: Unsustainably low prices for generics are preventing some manufacturers from producing them, while biosimilars are blocked by policies that favor originator drugs, the Association for Accessible Medicines (AAM) argues.

Number 2: Pfizer said it has made a business decision to cease production of biosimilars at a $350 million plant it built recently in Hangzhou, China.

Number 1: The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.